|
|
|
|
| LEADER |
04915nam a2200493 4500 |
| 001 |
ocn882252486 |
| 003 |
OCoLC |
| 005 |
20180501122019.0 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
140616t20142014caua ob 001 0 eng d |
| 040 |
|
|
|a E7B
|b eng
|e rda
|e pn
|c E7B
|d OCLCO
|d OPELS
|d OCLCF
|d EBLCP
|d OCLCQ
|d UAB
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 881162177
|
| 020 |
|
|
|a 9780128003176
|q (electronic bk.)
|
| 020 |
|
|
|a 0128003170
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128002490
|
| 035 |
|
|
|a (OCoLC)882252486
|z (OCoLC)881162177
|
| 050 |
|
4 |
|a RC267
|b .A383 2014eb
|
| 082 |
0 |
4 |
|a 616.9940072
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Advances in cancer research.
|n Volume one hundred and twenty one /
|c edited by Kenneth D. Tew, Paul B. Fisher.
|
| 264 |
|
1 |
|a San Diego, California :
|b Academic Press,
|c 2014.
|
| 264 |
|
4 |
|c ©2014
|
| 300 |
|
|
|a 1 online resource (461 pages) :
|b illustrations (some color), graphs
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references at the end of each chapters and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ebrary, viewed June 15, 2014).
|
| 520 |
|
|
|a Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
|
| 505 |
0 |
|
|a Front Cover; Advances in Cancer Research; Copyright; Contents; Contributors; Chapter One: Glial Progenitors as Targets for Transformation in Glioma; 1. Introduction; 2. Glial Cell Lineages; 3. Glioma Subgroups and Cell of Origin; 4. H3F3A Mutations Drive Gliomagenesis in Separate Brain Regions; 4.1. Regulation of DNA methylation by K27 and G34 H3F3A mutations; 4.2. Chromosome and Myc aberrations in H3F3A mutant glioblastoma; 4.3. Delineating the cell of origin for K27 and G34 H3F3A mutant glioblastoma; 5. Gliomagenesis and Mutations in Isocitrate Dehydrogenase Genes.
|
| 505 |
8 |
|
|a 5.1. Models of IDH-mutant gliomas5.2. Glial progenitor-origin for IDH-mutant gliomas; 6. Proneural-to-Mesenchymal Transition in Glioma; 6.1. Mesenchymal phenotype as a function of glioma subgroup; 6.2. Transcriptional master regulators of PMT in glioma; 6.3. Influence of the tumor microenvironment on the mesenchymal phenotype; 7. Relationship Between GSCs and Glial Progenitors; 7.1. Polycomb gene family; 7.2. NOTCH; 7.3. Sonic hedgehog; 7.4. Wingless; 8. Targeted Therapy in Glioma; 8.1. Epidermal growth factor gene family; 8.2. Targeting the proneural subgroup by PDGFR inhibition.
|
| 505 |
8 |
|
|a 8.3. Targeting the mesenchymal phenotype through c-MET inhibition8.4. Treatment-resistance associated with RTK inhibition; 8.4.1. RTK cooperativity; 8.4.2. Redundant activation of PI3K/mTOR; 8.4.3. Feedback loops; 8.4.4. Activation of alternative survival pathways; 8.5. Therapeutic targeting of IDH-mutant gliomas; 9. Concluding Remarks and Future Perspectives; Acknowledgments; References; Further Reading; Chapter Two: Therapeutic Cancer Vaccines; 1. Introduction; 2. Cancer Vaccine Targets; 3. Spectrum of Current Therapeutic Cancer Vaccine Platforms.
|
| 505 |
8 |
|
|a 3.1. An example of optimizing vaccine potency3.2. Vaccine/vaccine combinations; 4. Animal Models to Evaluate Cancer Vaccines: Pros and Cons; 5. Types of Immunotherapy; 5.1. Vaccine therapy and adoptive T-cell transfer: A study in contrasts; 6. The Importance of Antigen Cascade in Vaccine-Mediated Therapeutic Responses; 7. TRICOM-Based Vaccines: Clinical Studies; 8. Prostate Cancer Clinical Trials; 8.1. PSA-TRICOM (PROSTVAC) studies; 8.2. Vaccines and tumor growth rates; 8.3. A case report: Analysis of a prostate cancer patient over an 18-year period; 9. Vaccine Combination Therapies.
|
| 505 |
8 |
|
|a 10. Combination Therapies-Preclinical Studies10.1. Vaccine and radiation synergy; 10.2. Vaccines in combination with chemotherapy; 10.3. Vaccine in combination with small molecule targeted therapies; 10.4. The effect of nonimmune therapeutic interventions on immune cells; 11. Influence of the Tumor Microenvironment and Immunosuppressive Factors; 12. Vaccine Combination Therapies-Clinical Studies; 13. Biomarkers; 14. Vaccine Targets Involved in Tumor Progression and Drug Resistance; 15. Concluding Remarks; References.
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Cancer
|x Mortality.
|
| 650 |
|
7 |
|a Cancer
|x Mortality.
|2 fast
|0 (OCoLC)fst00845399
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Tew, Kenneth D.,
|e editor.
|
| 700 |
1 |
|
|a Fisher, Paul B.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Advances in cancer research. Volume one hundred and twenty one.
|d San Diego, California : Academic Press, ©2014
|h xii, 426 pages
|z 9780128002490
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/0065230X/121
|z Full Text via HEAL-Link
|
